Moderna, Inc. (MRNA)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$150.81
-2.24%
Investru Score
38.8 / 100
Weak
Why is MRNA moving?
MRNA is down 2.24% today, a pullback within its broader uptrend.
Business overview
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Bull case
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Bear case
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Want the complete AI research memo? Unlock full stock analysis →
Score breakdown
- Financial Quality
- 9
- Growth
- 43
- Profitability
- 13
- Balance Sheet
- 88
- Valuation
- 24
- Momentum
- 95
Financial quality
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
- ROIC
- -30.5%
- ROE
- -32.6%
- FCF Margin
- -106.2%
- Free Cash Flow (TTM)
- $-2.1B
- Earnings Quality (OCF ÷ Net Income)
- 0.7x
Valuation
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- PEG (P/E ÷ EPS Growth)
- Data unavailable
- Company Median PEG
- Data unavailable
- Price / Sales
- 35.1x
- EV / EBITDA
- Data unavailable
- FCF Yield
- -3.5%
Key risks
- AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.(Probability: Medium · Impact: Medium)
Latest earnings
- Q2 FY26 EPS
- $-1.97
- Estimate
- Data unavailable
- Surprise
- Data unavailable
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
SEC filings
- 10-Q · Q2 FY26 · period ended 2026-06-30Filed 2026-07-31
- 10-Q · Q1 FY26 · period ended 2026-03-31Filed 2026-05-01
- 10-K · FY25 · period ended 2025-12-31Filed 2026-02-20
- 10-Q · Q3 FY25 · period ended 2025-09-30Filed 2025-11-06
- 10-Q · Q2 FY25 · period ended 2025-06-30Filed 2025-08-01
- 10-K · FY24 · period ended 2024-12-31Filed 2025-02-21
- 10-K · FY23 · period ended 2021-12-31Filed 2024-02-23
- 10-K · FY23 · period ended 2022-12-31Filed 2024-02-23
- 10-K · FY23 · period ended 2023-12-31Filed 2024-02-23
Event filings (8-K) aren't covered by this page's data source yet — only 10-K/10-Q are shown above.
Market cap $59.4B · 52-week range $22.28–$176.66 · market data as of Sep 2, 2026, 4:00 PM ET · latest SEC filing: 2023-08-03
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze MRNA with Investru AINot investment advice. Investru AI summarizes public data and AI-generated analysis for informational purposes only.